AVAPRO Drug Patent Profile

When do Avapro patents expire, and when can generic versions of Avapro launch?

Avapro is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in AVAPRO is irbesartan. There are thirty-eight drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the irbesartan profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Avapro

A generic version of AVAPRO was approved as irbesartan by TEVA PHARMS on March 30^th, 2012.

Summary for AVAPRO

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for AVAPRO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVAPRO	Tablets	irbesartan	75 mg, 150 mg and 300 mg	020757	1	2004-05-25

US Patents and Regulatory Information for AVAPRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-001	Sep 30, 1997		DISCN	Yes	No
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-002	Sep 30, 1997	AB	RX	Yes	No
Sanofi Aventis Us	AVAPRO	irbesartan	TABLET;ORAL	020757-003	Sep 30, 1997	AB	RX	Yes	Yes

International Patents for AVAPRO

See the table below for patents covering AVAPRO around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H08333253	IRBESARTAN CONTAINING PHARMACEUTICAL COMPOSITION
Lithuania	3376	N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, PROCESS FOF THEIR PREPARATION, INTERMEDIATES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION
New Zealand	329547	PHARMACEUTICAL COMPOSITIONS COMPRISING IRBESARTAN AND HYDROCHLOROTHIAZIDE

Supplementary Protection Certificates for AVAPRO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454511	99C0009	Belgium		PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0454511	98C0028	Belgium		PRODUCT NAME: IRBESARTAN; NATL. REGISTRATION NO/DATE: EU/1/97/046/001 19970827; FIRST REGISTRATION: CH 54250 02 19970815
0454511	C990006	Netherlands		PRODUCT NAME: IRBESARTAN, DESGEWENST IN DE VORM VAN EEN ZOUT EN/OF EEN HYDRAAT, EN HYDROCHLOORTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 - EU/1/98/086/006 19981015

Avapro (Irbesartan): Investment and Fundamentals Analysis

Last updated: February 3, 2026

---

What is Avapro (Irbesartan)?

Avapro, with the active ingredient irbesartan, is an angiotensin II receptor blocker (ARB) approved by the U.S. Food and Drug Administration (FDA) in 2002. It is primarily prescribed for hypertension and diabetic nephropathy. Irbesartan belongs to a widely used class of medications targeting the renin-angiotensin system (RAS) to treat cardiovascular and renal conditions.

---

Market Overview and Growth Drivers

Market Size (2022 Estimates)

• The global hypertension treatment market was valued at approximately $33 billion in 2022.
• The ARB segment accounts for over 35% of this market, with irbesartan representing a significant proportion within ARBs.

Key Competitors

• Losartan (Cozaar)
• Valsartan (Diovan)
• Olmesartan (Benicar)
• Telmisartan (Micardis)

Irbesartan’s market share has declined due to patent expirations and generic competition but remains a relevant option within clinicians' prescriptions.

Key Growth Drivers

• Increasing prevalence of hypertension and type 2 diabetes.
• Rising awareness of cardiovascular and renal health.
• Patent expiration for branded formulations in many markets, leading to generic proliferation.

---

Patent and Regulatory Status

• The original patent for Irbesartan expired in 2012 in the U.S.
• Multiple generic versions have entered the market since then, exerting pricing pressure.
• Regulatory guidelines now influence prescriber preferences, favoring cost-effective generics.

Sales and Revenue Trends

• Estimated U.S. sales peaked at approximately $250 million annually prior to patent expiry (IQVIA, 2022).
• Post-generic entry, sales declined by over 50%, stabilizing around $100-$150 million annually depending on market and healthcare policies.

Cost and Pricing Dynamics

• Brand-name Avapro priced higher than generics, which dominate the market.
• Average price of a branded Irbesartan prescription (~$60 per month) versus generics (~$10–$20 per month).

Investment Considerations

Factor	Impact/Implication
Patent expiry	Led to generic competition, reducing revenues.
Market penetration	Generic presence limits potential for revenue growth in mature markets.
R&D pipeline for ARBs	Limited; most innovation centers on combination therapies or new drug classes.
Regulatory environment	Price controls and formulary restrictions could affect sales volume.
Geographic expansion	Emerging markets show increasing hypertension prevalence, potentially revitalizing sales.

---

Financial Fundamentals

Revenue and Profitability

• Historic revenue estimation: $250 million pre-2012, declining post-patent expiry.
• Gross margins for irbesartan generics: typically 60-70%.
• Brands like Avapro had margins >80% before patent expiry but have since compressed.

R&D and Lifecycle Status

• No current R&D pipeline specifically for irbesartan.
• Existing formulations are mature; innovation focused on combination therapies.

Cost Structure

• R&D minimal due to generic status.
• Manufacturing costs low; predominant expenses are marketing, distribution, and regulatory compliance.

---

Strategic Outlook

• Investment in Avapro alone is limited post-generics.
• Focus shifts to company portfolio management and pipeline diversification.
• Developing combination drugs or novel ARBs could expand market share.
• Diversification into emerging markets offers growth but involves regulatory and price competition risks.

---

Risks and Opportunities

Risks:

• Erosion of market share due to generic competition.
• Pricing pressure amid evolving healthcare policies.
• Lack of R&D investment reduces innovation potential.

Opportunities:

• Licensing deals or co-marketing with generic producers.
• Focus on niche indications or combination drugs.
• Entry into emerging markets with high hypertension prevalence.

---

Conclusion

Investment in Avapro as a standalone product offers limited growth prospects due to patent expiration and extensive generic competition. The pharmaceutical landscape favors diversified portfolios, especially those with innovation pipelines. Companies leveraging brand differentiation, positioning within combination therapies, or broad geographical expansion are better positioned for growth.

---

Key Takeaways

• Avapro's patent expired in 2012; the product now exists mainly as a generic.
• The ARB market is mature, with limited room for growth in developed markets.
• Emerging markets provide growth opportunities but come with regulatory and price competition risks.
• The absence of R&D for irbesartan restricts future pipeline potential.
• Strategic investments should focus on company-wide diversification and pipeline vitality, not on Avapro alone.

---

FAQs

1. Is Avapro profitable for the manufacturer today?
Profitability has decreased post-generic entry, with margins compressed. It remains a revenue contributor but no longer a high-margin product.

2. Will there be new formulations or patents for Avapro?
Current trends favor innovation in combination therapies rather than reformulation of existing drugs like irbesartan.

3. How does Avapro compare to other ARBs?
It is comparable in efficacy but less favored due to patent expiry and generic competition. Market share depends on formulary decisions and regional preferences.

4. Are there emerging markets where Avapro could regain sales?
Yes, high hypertension prevalence and lower healthcare costs in regions like Asia and Africa provide growth avenues, contingent on regulatory approvals.

5. Should investors focus on companies with extensive ARB portfolios?
Yes. Firms with diversified ARB offerings, innovative pipelines, and regional expansion strategies are better positioned long-term.

---

References

[1] IQVIA, "Market Data for Hypertension Treatments," 2022.